3 Fermentation-Based Ingredients Maker, Custom Synthesis Specialist and Research-Driven Pharma Company Stocks With a Strong Future Roadmap: Concord Biotech, Neuland Laboratories and Glenmark Pharmaceuticals
- October 26, 2026
- Posted by: Harsh Piplani
- Category: Best Stocks
Concord Biotech, Neuland Laboratories and Glenmark Pharmaceuticals: ROE of 12.9% to 28.1% and FY22 to FY26 revenue CAGR of 8.7% to 21.1%. Prices as of 23 Oct 2026.
Quick Answer
The three biopharma, API and innovation pharma stocks to watch are Concord Biotech, Neuland Laboratories and Glenmark Pharmaceuticals. Their return on equity ranges from 12.9% to 28.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.7% to 21.1%. Glenmark Pharmaceuticals has the highest return on equity at 28.1%, while Neuland Laboratories has the fastest revenue growth at 21.1% a year. Prices are based on the 23 October 2026 close, and this article is educational, not investment advice.
Biopharma, API and innovation pharma stocks let investors follow companies that serve a growing part of the Indian economy. Concord Biotech, Neuland Laboratories and Glenmark Pharmaceuticals cover a fermentation-based ingredients maker, a custom synthesis specialist and a research-driven pharma company.
This list covers three biopharma, API and innovation pharma stocks with complete current figures: Concord Biotech, Neuland Laboratories and Glenmark Pharmaceuticals. Every figure comes from the latest reported financials and the 23 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Biopharma, API and Innovation Pharma Stocks?
Biopharma, API and innovation pharma stocks are listed drug makers that supply fermentation ingredients, complex active ingredients and branded and generic medicines. Their earnings depend on customer contracts, regulatory approvals and the progress of new products.
Biopharma, API and Innovation Pharma Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Concord Biotech | 1,229.3 | 13,421 | 49.2 | 36.0 | 12.9 | 0.00 |
| Neuland Laboratories | 18,865 | 24,665 | 49.5 | 36.0 | 19.4 | 0.16 |
| Glenmark Pharmaceuticals | 2,166.6 | 60,103 | 33.4 | 35.7 | 28.1 | 0.06 |
On valuation, Glenmark Pharmaceuticals trades at a P/E below the industry P/E, while Concord Biotech and Neuland Laboratories trade above it, which reflects the growth the market already expects. Readers comparing biopharma, API and innovation pharma stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Biopharma, API and Innovation Pharma Stocks Have a Strong Roadmap in India?
Biopharma, API and innovation pharma stocks have a strong roadmap in India because global innovators outsource complex manufacturing, and Indian firms with strong science are moving into specialty and innovative medicines.
- Complex chemistry. Few suppliers can make difficult molecules at scale.
- Custom manufacturing. Innovator contracts bring multi-year demand.
- Innovation pipeline. New drug programmes create fresh growth options.
Why Concord Biotech Features Among These Biopharma, API and Innovation Pharma Stocks
Among the biopharma, API and innovation pharma stocks on this list, Concord Biotech is a Gujarat-based biopharma company that makes fermentation-based active ingredients such as immunosuppressants, oncology drugs and anti-infectives for global pharma customers.
In the June 2026 quarter, revenue grew 24.2% year on year to Rs 270 crore, while net profit rose 31.0% to Rs 57.7 crore. Revenue rose from Rs 736 crore in FY22 to Rs 1,107 crore in FY26, a compound annual growth rate of 10.7%.
Net profit grew from Rs 175 crore in FY22 to Rs 259 crore in FY26, which works out to a compound annual growth rate of 10.3%. The company has a return on equity of 12.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 13,421 crore. The stock trades at a P/E of 49.2, above the industry P/E of 36.0.
Roadmap: The company is among the leading global suppliers in its key immunosuppressant molecules and is moving into formulations and new fermentation products. Its backward integration and regulatory approvals support its position.
What to watch: Monitor the pace of new product introductions and the contribution from formulations.
Why Neuland Laboratories Features Among These Biopharma, API and Innovation Pharma Stocks
Among the fermentation ingredient company shares on this list, Neuland Laboratories, based in Hyderabad, makes active pharmaceutical ingredients for generic drugs and runs a custom manufacturing business that supplies innovator companies.
The company has a return on equity of 19.4%, a debt to equity ratio of 0.16 and a market capitalisation of Rs 24,665 crore. The stock trades at a P/E of 49.5, above the industry P/E of 36.0.
Revenue rose from Rs 953 crore in FY22 to Rs 2,053 crore in FY26, a compound annual growth rate of 21.1%. Net profit grew from Rs 63.8 crore in FY22 to Rs 364 crore in FY26, which works out to a compound annual growth rate of 54.5%.
Roadmap: The company is moving up the value chain by growing custom manufacturing, which carries longer contracts and better margins than commodity generic ingredients. A strong order book for development-stage molecules gives visibility on multi-year volumes.
What to watch: Custom manufacturing revenue can move between quarters, so review the full-year trend.
Why Glenmark Pharmaceuticals Features Among These Biopharma, API and Innovation Pharma Stocks
Among the three companies on this list, Glenmark Pharmaceuticals is a research-driven pharma company with branded generics in India and other emerging markets, generics in the United States and Europe, and an innovation arm focused on new drugs.
Revenue rose from Rs 12,472 crore in FY22 to Rs 17,443 crore in FY26, a compound annual growth rate of 8.7%. Net profit grew from Rs 994 crore in FY22 to Rs 1,362 crore in FY26, which works out to a compound annual growth rate of 8.2%.
In the June 2026 quarter, revenue grew 24.1% year on year to Rs 4,084 crore. The company has a return on equity of 28.1%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 60,103 crore. The stock trades at a P/E of 33.4, below the industry P/E of 35.7.
Roadmap: The company is strengthening its dermatology and respiratory franchises and advancing its innovation pipeline, which could add higher-value income. Growth in India and emerging markets supports steady sales.
What to watch: Track new product launches, progress in the innovation pipeline and balance sheet strength.
Concord Biotech vs Neuland Laboratories vs Glenmark Pharmaceuticals on Key Financials
The table below sets the three biopharma, API and innovation pharma stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Concord Biotech | 736 | 1,107 | 10.7% | 259 | 23.4% |
| Neuland Laboratories | 953 | 2,053 | 21.1% | 364 | 17.7% |
| Glenmark Pharmaceuticals | 12,472 | 17,443 | 8.7% | 1,362 | 7.8% |
Glenmark Pharmaceuticals posts the highest return on equity in this group at 28.1%. Glenmark Pharmaceuticals has the largest FY26 revenue at Rs 17,443 crore, and Neuland Laboratories shows the fastest revenue growth with a 21.1% compound annual rate. A useful habit with biopharma, API and innovation pharma stocks is to check each new quarterly result against the capacity plans the company described earlier.
Key Risks to Check Before Investing in Biopharma, API and Innovation Pharma Stocks
Every theme carries risks that deserve a check before any decision. For these biopharma, API and innovation pharma stocks, the main points are:
- Regulatory checks. Plant inspections can affect approvals.
- Contract timing. Large orders can shift between quarters.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter biopharma, API and innovation pharma stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Biopharma, API and Innovation Pharma Stocks
Biopharma, API and innovation pharma stocks reward investors who follow demand trends, order books and margins together. Concord Biotech, Neuland Laboratories and Glenmark Pharmaceuticals each have a clear plan to grow. Based on the 23 October 2026 close, Concord Biotech trades at Rs 1,229.3, Neuland Laboratories at Rs 18,865 and Glenmark Pharmaceuticals at Rs 2,166.6.
Download the Univest iOS App or Univest Android App to track biopharma, API and innovation pharma stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are biopharma, API and innovation pharma stocks?
Ans. Biopharma, API and innovation pharma stocks are listed drug makers that supply fermentation ingredients, complex active ingredients and branded and generic medicines. Their earnings depend on customer contracts, regulatory approvals and the progress of new products. This list looks at three of them, Concord Biotech, Neuland Laboratories and Glenmark Pharmaceuticals, using reported FY22 to FY26 financials and the 23 October 2026 closing prices.
Which biopharma, API and innovation pharma stocks are covered in this list?
Ans. This list covers Concord Biotech, Neuland Laboratories and Glenmark Pharmaceuticals. Based on the 23 October 2026 close, Concord Biotech traded at Rs 1,229.3, Neuland Laboratories at Rs 18,865 and Glenmark Pharmaceuticals at Rs 2,166.6. Their return on equity ranges from 12.9% to 28.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.7% to 21.1%.
Why do biopharma, API and innovation pharma stocks have a strong future roadmap in India?
Ans. Biopharma, API and innovation pharma stocks have a strong roadmap in India because global innovators outsource complex manufacturing, and Indian firms with strong science are moving into specialty and innovative medicines. The main drivers are as follows. Complex chemistry. Few suppliers can make difficult molecules at scale. Custom manufacturing. Innovator contracts bring multi-year demand. Innovation pipeline. New drug programmes create fresh growth options. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Concord Biotech performed financially?
Ans. Revenue rose from Rs 736 crore in FY22 to Rs 1,107 crore in FY26, a compound annual growth rate of 10.7%. Net profit grew from Rs 175 crore in FY22 to Rs 259 crore in FY26, which works out to a compound annual growth rate of 10.3%. In the June 2026 quarter, revenue grew 24.2% year on year to Rs 270 crore, while net profit rose 31.0% to Rs 57.7 crore. The company has a return on equity of 12.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 13,421 crore. The stock trades at a P/E of 49.2, above the industry P/E of 36.0. Looking ahead, the company is among the leading global suppliers in its key immunosuppressant molecules and is moving into formulations and new fermentation products. Its backward integration and regulatory approvals support its position.
How has Neuland Laboratories performed financially?
Ans. Revenue rose from Rs 953 crore in FY22 to Rs 2,053 crore in FY26, a compound annual growth rate of 21.1%. Net profit grew from Rs 63.8 crore in FY22 to Rs 364 crore in FY26, which works out to a compound annual growth rate of 54.5%. The company has a return on equity of 19.4%, a debt to equity ratio of 0.16 and a market capitalisation of Rs 24,665 crore. The stock trades at a P/E of 49.5, above the industry P/E of 36.0. Looking ahead, the company is moving up the value chain by growing custom manufacturing, which carries longer contracts and better margins than commodity generic ingredients. A strong order book for development-stage molecules gives visibility on multi-year volumes.
How has Glenmark Pharmaceuticals performed financially?
Ans. Revenue rose from Rs 12,472 crore in FY22 to Rs 17,443 crore in FY26, a compound annual growth rate of 8.7%. Net profit grew from Rs 994 crore in FY22 to Rs 1,362 crore in FY26, which works out to a compound annual growth rate of 8.2%. In the June 2026 quarter, revenue grew 24.1% year on year to Rs 4,084 crore. The company has a return on equity of 28.1%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 60,103 crore. The stock trades at a P/E of 33.4, below the industry P/E of 35.7. Looking ahead, the company is strengthening its dermatology and respiratory franchises and advancing its innovation pipeline, which could add higher-value income. Growth in India and emerging markets supports steady sales.
What risks should investors check before buying biopharma, API and innovation pharma stocks?
Ans. Investors should check a few risks before buying biopharma, API and innovation pharma stocks. Regulatory checks. Plant inspections can affect approvals. Contract timing. Large orders can shift between quarters. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of biopharma, API and innovation pharma stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 23 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
